Rebinyn
Biological
Novo Nordisk AS
Total Payments
$1.1M
Transactions
574
Doctors
159
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $78,271 | 35 | 16 |
| 2023 | $313,760 | 164 | 58 |
| 2022 | $717,277 | 375 | 105 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $747,310 | 186 | 67.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $217,336 | 71 | 19.6% |
| Consulting Fee | $82,785 | 39 | 7.5% |
| Travel and Lodging | $46,446 | 94 | 4.2% |
| Food and Beverage | $15,301 | 180 | 1.4% |
| Education | $129.08 | 4 | 0.0% |
Payments by Type
Research
$747,310
186 transactions
General
$361,998
388 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN7999-3895 | Novo Nordisk AS | $656,837 | 0 |
| NN7999-3774 | Novo Nordisk AS | $90,474 | 0 |
Top Doctors Receiving Payments for Rebinyn
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $747,332 | 187 |
| , MD | Pediatric Hematology-Oncology | Beaufort, SC | $53,072 | 42 |
| , MD | Pediatrics | Nashville, TN | $47,157 | 40 |
| , M.D | Pediatrics | Orlando, FL | $42,064 | 27 |
| , MD | Pediatric Hematology-Oncology | Slidell, LA | $36,139 | 20 |
| , M.D | Pediatrics | Las Vegas, NV | $33,710 | 18 |
| , M.D | Hematology | Los Angeles, CA | $25,767 | 19 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $20,187 | 12 |
| , M.D | Internal Medicine | Nashville, TN | $18,170 | 11 |
| Richard Lemons | Pediatric Hematology-Oncology | Salt Lake City, UT | $10,446 | 5 |
| Dennis Borrero | Pediatrics | Orlando, FL | $8,105 | 5 |
| , NP-C | Pediatrics | Sacramento, CA | $6,477 | 7 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $5,323 | 4 |
| , MD | Pediatrics | Miami, FL | $5,077 | 5 |
| , M.D | Pediatrics | Chicago, IL | $4,975 | 3 |
| , M.D | Internal Medicine | Houston, TX | $4,860 | 3 |
| , M.D | Pediatric Hematology-Oncology | San Juan, PR | $4,718 | 3 |
| , MD | General Practice | Torrance, CA | $4,675 | 2 |
| , MD | Hematology & Oncology | New York, NY | $4,463 | 1 |
| , M.D | Pediatrics | Peoria, IL | $3,400 | 2 |
| , M.D | Pediatrics | Charlotte, NC | $3,334 | 2 |
| , MD | Pediatric Hematology-Oncology | Redlands, CA | $1,834 | 1 |
| , M.D | Hematology | Pittsburgh, PA | $1,620 | 1 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $1,200 | 1 |
| , M.D | Pediatric Hematology-Oncology | Milwaukee, WI | $1,020 | 1 |
Ad
Manufacturing Companies
- Novo Nordisk AS $747,310
- Novo Nordisk Inc $357,833
- Novo Nordisk Health Care AG $4,165
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 159
- Transactions 574
About Rebinyn
Rebinyn is a biological associated with $1.1M in payments to 159 healthcare providers, recorded across 574 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2022 to 2024. In 2024, $78,271 was paid across 35 transactions to 16 doctors.
The most common payment nature for Rebinyn is "Unspecified" ($747,310, 67.4% of total).
Rebinyn is associated with 2 research studies, including "NN7999-3895" ($656,837).